CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenue	$ 19,018	$ 1,659	$ 21,999	$ 5,260
Costs and expenses:
Cost of revenue	923	1,099	3,146	3,564
Research and development expense	23,656	13,976	56,741	29,711
General and administrative expense	5,813	5,979	17,987	16,676
Licensing	7,300		7,300
Revaluation of contingent consideration	2,200	900	(2,400)	22,139
Total costs and expenses	39,892	21,954	82,774	72,090
Loss from operations	(20,874)	(20,295)	(60,775)	(66,830)
Other income (expense), net	922	(851)	1,502	(1,231)
Net loss	$ (19,952)	$ (21,146)	$ (59,273)	$ (68,061)
Net loss per share, basic	$ (0.30)	$ (0.35)	$ (0.92)	$ (1.23)
Net loss per share, diluted	$ (0.30)	$ (0.35)	$ (0.92)	$ (1.23)
Weighted average common shares outstanding, basic	66,675,337	61,219,321	64,718,008	55,215,037
Weighted average common shares outstanding, diluted	66,675,337	61,219,321	64,718,008	55,215,037
Other comprehensive (loss) income:
Unrealized gain (loss) on marketable securities, net of tax of $0	$ (139)	$ 5	$ (1,241)	$ (5)
Foreign currency translation adjustment		176		96
Total other comprehensive (loss) income	(139)	181	(1,241)	91
Comprehensive loss	(20,091)	(20,965)	(60,514)	(67,970)
Contract research
Revenues:
Total revenue	1,090	1,415	3,529	4,556
Licensing
Revenues:
Total revenue	17,898	214	18,378	612
Other
Revenues:
Total revenue	$ 30	$ 30	$ 92	$ 92